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Abstract: Nypa fruticans Wurmb. vinegar, commonly known as nipa palm vinegar (NPV)
has been used as a folklore medicine among the Malay community to treat diabetes. Early
work has shown that aqueous extract (AE) of NPV exerts a potent antihyperglycemic effect.
Thus, this study is conducted to evaluate the effect of AE on postprandial hyperglycemia in
an attempt to understand its mechanism of antidiabetic action. AE were tested via in vitro
intestinal glucose absorption, in vivo carbohydrate tolerance tests and spectrophotometric
enzyme inhibition assays. One mg/mL of AE showed a comparable outcome to the use
of phloridzin (1 mM) in vitro as it delayed glucose absorption through isolated rat jejunum
more effectively than acarbose (1 mg/mL). Further in vivo confirmatory tests showed AE
(500 mg/kg) to cause a significant suppression in postprandial hyperglycemia 30 min
following respective glucose (2 g/kg), sucrose (4 g/kg) and starch (3 g/kg) loadings in normal
rats, compared to the control group. Conversely, in spectrophotometric enzymatic assays, AE
showed rather a weak inhibitory activity against both α-glucosidase and α-amylase when
compared with acarbose. The findings suggested that NPV exerts its anti-diabetic effect
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by delaying carbohydrate absorption from the small intestine through selective inhibition of
intestinal glucose transporters, therefore suppressing postprandial hyperglycemia.
Keywords: Nypa fruticans Wurmb; vinegar; postprandial hyperglycemia; oral glucose
tolerance test; alpha glucosidase; acarbose
1. Introduction
Diabetes mellitus (DM) is a chronic metabolic disorder caused by impairment of insulin production by
pancreatic β cells and/or defects in insulin action [1]. Such abnormalities lead to chronic hyperglycemia,
which, in turn, deranges the metabolism of carbohydrates, proteins and fats, and results in several
macro- and micro-vascular complications. Postprandial hyperglycemia is one of the earliest detectable
abnormalities signaling type 2 diabetes mellitus [2]. Relevant clinical studies suggested that it was
an important factor contributing to the development of diabetes complications [3,4]. Hence, to
prevent or slow the manifestation of diabetes-related complication, good management of postprandial
hyperglycemia is critical early in the treatment of diabetes mellitus. One way to achieve controlled
postprandial blood glucose levels is to slow down glucose absorption in the intestines by inhibition of
the action of certain carbohydrate-hydrolyzing enzymes, namely pancreatic α-amylase, and intestinal
α-glucosidase and glucose transporters like SGLT 1 and GLUT 2 [5].
In the 1990s, α-glucosidase inhibitors such as acarbose, voglibose and miglitol were approved as
oral drugs for the treatment of diabetes mellitus. Currently, they are widely used, either alone or in
combination with diet and insulin therapy, in patients with type 1 and type 2 DM [6,7]. Furthermore,
canagliflozin and dapagliflozin were among the earliest glucose transporter SGLT2 inhibitors approved
by the Food and Drug Administration (FDA) for the purpose of achieving better glycemic control in
adults with type 2 diabetes mellitus. Aside from these drugs, many other SGLT inhibitors are being
developed and are currently undergoing clinical trials [8].
Nypa fruticans Wurmb. vinegar, locally known as nipa palm vinegar (NPV) is a traditional preparation
produced by the fermentation of nira, an alcoholic beverage of nipa palm (Nypa fruticans Wurmb.) sap.
It is commonly consumed throughout East Asia [9]. Added to drinking water, NPV is taken before meals
and at bedtime. It has been shown that the ingestion of vinegar reduces postprandial hyperglycemia in
type 2 diabetic patients receiving meals of moderate glycaemic index [10]. In our previous studies,
chronic administration of NPV aqueous extract at a dose of 1000 mg/kg caused a significant blood
glucose lowering effect and improved the level of insulin of diabetic rats [11]. Hence, the effects of the
aqueous extract on intestinal glucose absorption and postprandial hyperglycemia were further studied in
an attempt to understand the mechanisms of its blood glucose lowering activity.
2. Experimental Section
2.1. Chemicals
α-glucosidase, porcine α-amylase and D(+)-glucose were purchased from Sigma Aldrich Chemical
(St. Louis, MO, USA). Sucrose and starch were supplied by Sigma, Life Science (Waltham, MA, USA).
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Phloridzin and acarbose (Glucobayr) were respectively obtained from Sigma-Aldrich (St. Louis, MO,
USA) and Bayer AG (Wuppertal, Germany). All reagents were of analytical grade.
2.2. Plant Preparation and Extraction
NPV used in the study was supplied by a local producer from Titi Bakong, Yan, Kedah, Malaysia
(5˝4819.4211 N, 100˝22135.3211 E). Several parts of nipa palm were authenticated by Rahmad Zakaria at
the Herbarium Unit, School of Biological Sciences, Universiti Sains Malaysia and the voucher specimens
were deposited at the same unit with the voucher number of USM. Herbarium 11541. NPV was made by
the fermentation of nipa palm sap “nira”. In brief, nira was stored in a polyethylene barrel for 44 days at
room temperature to allow a slow and natural fermentation process of alcohol and acetic acid contents.
Fully fermented product, NPV with a pH around 3.2 was then filtered, poured into bottles and made
ready for consumption.
NPV was extracted using the liquid–liquid extraction approach described by Qiu et al. [12] with
minor modifications. The vinegar (500 mL) was concentrated to a final volume of 250 mL at 37 ˝C
using a vacuum rotary evaporator (Labortechnik, AG CH-9230, Postfach, Flawil, Switzerland). The
concentrated vinegar was first extracted with ethyl acetate in a ratio of 1:1 using a separatory funnel.
The upper layer of ethyl acetate was then separated, and the residue, the aqueous layer, was collected.
The liquid-liquid partitioning step between ethyl acetate and aqueous NPV was repeated again for three
batches. The aqueous layer containing potential bioactive was collected, pooled, concentrated under
reduced pressure at 40 ˝C using a vacuum rotary evaporator to remove traces of organic solvent, and
lyophilized using a freeze-drier (Labconco Corporation, Kansas, MO, USA) to yield the aqueous extract
(yield 85%). Finally, the aqueous extract (AE) was stored in the freezer at ´4 ˝C until further use.
2.3. Animals
Healthy adult male Sprague-Dawley rats (200 to 250 g) were obtained from the Animal Research
and Service Centre (ARASC), USM. In order to acclimatize to the laboratory environment, prior to
experimentation, the animals were housed in a well-ventilated animal transit room and fed a standard
diet and water ad libitum for a period of seven days. The experiment procedure was approved
by the Animal Ethics Committe, Universiti Sains Malaysia (Approval number: USM/Animal Ethics
Approval/2011/(71)(326)).
2.4. Intestinal Glucose Absorption by the Everted Sac Technique
AE effect on glucose absorption via isolated rat jejunal sacs was studied according to the method of
Wilson & Wiseman [13], as described by Hassan et al. [14]. Following an overnight fast, a male Sprague
Dawley rat (250–300 g) was sacrificed and the abdominal wall was dissected. The jejunum was isolated
from the small intestine (20 to 50 cm from the pylorus), placed in a Tyrode buffer solution (342 mM
NaCl, 6.7 mM KCl, 5.9 mM CaCl2¨ 2H2O, 5.3 mM MgCl2, 59.5 mM NaHCO3, 2.08 mM NaH2PO2
and 5.5 mM glucose) and aerated with carbogen (95% O2 and 5% CO2). The jejunum was everted and
cut into 5-cm segments. Each segment, filled with 1 mL of the Tyrode solution, was formed into a sac
by tying both of its ends with cotton threads. Each sac was further incubated for 90 min at 37 ˝C in
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a test tube containing a total of 15 mL of the Tyrode solution. Added to the tubes, the test substances
were comprised of AE (1 mg/mL), acarbose (1 mg/mL) and phloridzin (0.001 M), respectively. The
tubes containing the Tyrode solution alone served as the negative control. The initial and final glucose
concentrations following the incubation period were measured using a chemistry analyser, Stat Fax
1937 (Awareness Technology Inc., Palm City, FL, USA); and the intestine glucose absorption could
be calculated as follows:
Amount of glucose absorbed pmg{g tissueweightq “ ppGbefore´Gafterq{Wintestineq (1)
where Gbefore and Gafter represented glucose concentrations (mg/dL) before and after incubation,
respectively; whereas Wintestine represented the weight of the intestinal segment (g).
2.5. Oral Glucose Tolerance Test (OGTT)
As detailed by Ali et al. [15], overnight-fasted non-diabetic rats were divided into five groups of six
rats each and received the treatment orally: Group 1 was given distilled water (10 mL/kg). Groups
2 and 3 were treated with acarbose (10 mg/kg) and phloridzin (200 mg/kg), respectively, to serve as
the positive controls. Groups 4 and 5 were treated with AE at the respective doses of 500 mg/kg and
250 mg/kg. Ten minutes after a single oral administration as above, the rats were challenged orally with
glucose at a dose of 2 g/kg B.W. Blood samples were taken from the tail tip at 0 (before treatment), 30,
60 and 120 min after the glucose challenge. Blood glucose levels were determined using a glucometer
(Accu-Check, Roche, Mexico City, Mexico) utilizing the glucose oxidase-peroxidase method. Areas
under the curve (AUC) were calculated using the trapezoidal method.
2.6. Oral Sucrose Tolerance Test (OSucTT)
The procedure mentioned in Section 2.5 was applied to a similar set of animals. However, sucrose, at
a dose of 4 g/kg B.W. was administered in place of glucose.
2.7. Oral Starch Tolerance Test (OSTT)
The same procedure as in Section 2.5 was applied. Starch was administered in place of glucose and
given at a dose of 3 g/kg B.W.
2.8. In Vitro Enzymatic Inhibition Study: α-Glucosidase
AE α-glucosidase inhibition activity was assessed spectrophotometrically as previously described by
Kwon et al. [16] with slight modifications. Briefly, 50-µL aliquots of AE at different concentrations
(6.25–100.00 mg/mL) were mixed with 100 µL of a 0.1 M phosphate buffer (pH 7.0) containing
0.5 U/mL of α-glucosidase to be incubated in a 96-well plate at 37 ˝C for 10 min. The control contained
a similar aliquot of the 0.1 M phosphate buffer solution instead of the extract. After incubation, 50 µL
of a solution containing 5 mM p-nitrophenyl-α-D-glucopyranoside (pNPG) in a 0.1 M phosphate buffer
(pH 7.0) were added to each well. The reaction mixture was further incubated at 37 ˝C for 5 min. The
absorbances at before and after the incubation period were recorded using a microplate reader (Power
Wave ˆ 340, BioTekr Instruments Inc., Winooski, VT, USA) at λmax 490 nm. Acarbose was served as
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the standard reference and treated similarly to the sample. The percentage of inhibition of the activity of
α-glucosidase was calculated using the following equation:
α ´ glucosidase inhibitory activity p%q “ rpAcontrol´Asampleq{Acontrols ˆ 100 (2)
where Acontrol represented the absorbance of the control. Asample represented the absorbance of the sample.
The concentration of the sample/acarbose required to inhibit 50% of the α-glucosidase activity (IC50)
was determined by the linear regression analysis.
2.9. In Vitro Enzymatic Inhibition Study: α-Amylase
AE α–amylase inhibition activity was studied according to the method described by Kwon et al. [16].
500 µL of AE and acarbose (standard α-amylase inhibitor) were each mixed with 500 µL of a 20 mM
sodium phosphate buffer (pH 6.9 with 6 mM sodium chloride) containing 0.5 mg/mL of α-amylase.
The control mixture contained a similar volume of the 20 mM sodium phosphate buffer in place of the
extract. The resulting solutions were incubated at 25 ˝C for 10 min. Then, 500 µL of a 1% starch
solution, prepared in 20 mM sodium phosphate buffer (pH 6.9 with 0.006 M sodium chloride), were
added. The final mixtures were incubated at 25 ˝C for 10 min as well; and the reaction was stopped
by the addition of 1.0 mL of dinitrosalicylic acid (DNSA), a colour reagent. Then, reaction tubes were
incubated in a boiling water bath (Buchi, B-491, Postfach, Flawil, Switzerland) for 5 min. Cooled down
to room temperature, the solutions were diluted with 10 mL of distilled water. Lastly, using a UV-250
UV–Visible spectrophotometer (Shimadzu Corporation, Tokyo, Japan), absorbance values were obtained
at λmax 540 nm; and the inhibitory activities of AE and acarbose were calculated as follows:
α ´ amylase inhibitory activity p%q “ rpAcontrol´Asampleq{Acontrols ˆ 100 (3)
where Acontrol denoted the absorbance of the control. Asample denoted the absorbance of the experimental
sample. The inhibitory activities of the samples against α-amylase were expressed as the percentage of
inhibition, and IC50 values were reported.
2.10. Statistical Analysis
Data was expressed as the mean ˘ standard error of the mean (SEM). Statistical significance was
assessed using one-way analysis of variance (ANOVA) followed by Dunnett’s Test or Tukey HSD (honest
significant difference) as the post hoc tests. p values less than 0.05 indicated statistical significance.
3. Results
3.1. AE Attenuates Intestinal Glucose Absorption
Figure 1 depicts the in vitro effects of AE, acarbose and phloridzin on intestinal glucose absorption,
as investigated using the everted jejunal sac technique. Acarbose, an α-glucosidase inhibitor, and
phloridzin, a SGLT inhibitor, were tested for comparison purposes. As shown below, in the absence
of test substances, the amount of absorbed glucose was 36.63 mg/g tissue weight. The presence of
phloridzin, however, caused a significantly reduced glucose absorption rate (p < 0.01) of 11.23 mg/g
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tissue weight (an inhibition of 69.34%) in comparison with the control. AE recorded a similar promising
outcome as the amount of glucose absorbed significantly decreased to 9.69 mg/g tissue weight (p < 0.01)
when compared to the control (a 73.54% reduction in absorption). On the other hand, acarbose caused
a 45.67% reduction in glucose absorption, as the absorption rate was 19.9 mg/g tissue weight only.
However, although the reduction percentage was quite high, it was not significant compared with the
control (p < 0.056).
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Figure 1. Effect of control, acarbose, phloridzin and aqueous extract (AE) of NPV
on intestinal glucose absorption by everte sac technique. Data is represented as
means ˘ S.E.M. (n = 6). ** p < 0.01 vs. the co trol group.
3.2. Oral Glucose Tolerance Test (OGTT) in Normal Rats
To confirm the intestinal inhibitory effect of AE, an in vivo glucose challenge test was carried out.
Figure 2 showed that in the normal control group (NC), the postprandial hyperglycemia levels caused by
2 g/kg of glucose loading reached 8.66 mmol/L 30 min after glucose administration. 60 min afterwards,
they decreased to 7.72 mmol/L and continued to reach an average of 5.6 mmol/L 120 min post-loading.
However, given at a dose of 500 mg/kg, compared with the control group, AE caused the elevation of
the blood glucose levels to be significantly suppressed (p < 0.01) at minute 30. Likewise, phloridzin
caused a significant (p < 0.01) suppression in the rise of the blood glucose levels 30 min after glucose
loading. Hence, it can be concluded that a dose of 500 mg/kg of AE exhibited a comparable effect to
phloridzin at a dose of 200 mg/kg in suppressing postprandial hyperglycemia. However, as the blood
glucose levels decreased naturally in the NC group, no statistical significance could be observed between
the NC, and AE and phloridzin groups later on. On the other hand, a dose of 10 mg/kg of acarbose did
not significantly suppress the rise in blood glucose levels after glucose loading throughout the course of
the study. As seen in Table 1, the area under the curve (AUC) of glucose tolerance for the AE-treated
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groups (AE 500; 765.9 ˘ 62.3 mmol¨min/L and AE 250; 742.8 ˘ 46.4 mmol¨min/L) was significantly
lower than that of the NC group (849.0˘ 59.5 mmol¨min/L) and comparable to those of both phloridzin
(798.3 ˘ 75.6 mmol¨min/L) and acarbose (816.0 ˘ 60.2 mmol¨min/L). AUC values corroborated with
the recorded blood glucose levels.
Figure 2 
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Figure 2. Effect of normal control (NC), acarbose, phloridzin and aqueous extract (AE) of
NPV on postprandial blood glucose levels in oral glucose tolerance test. Data is expressed
as means ˘ S.E.M. (n = 6). * p < 0.05, ** p < 0.01 vs. the NC group.
Table 1. Area under the curve (AUC) of postprandial glucose responses of normoglycemic
rats in oral glucose tolerance test (OGTT), oral sucrose tolerance test (OSucTT) and oral
starch tolerance test (OSTT).
Group 1
AUC (mmol¨min/L)
OGTT OSucTT OSTT
NC 851.7 ˘ 59.5 b 855.0 ˘ 58.8 c 840.6 ˘ 55.5 c
Acarbose 816.0 ˘ 60.2 ab 668.7 ˘ 58.9 a 623.7 ˘ 45.8 a
Phloridzin 798.3 ˘ 75.6 ab 676.2 ˘ 63.9 a 685.5 ˘ 62.0 ab
AE 500 756.3 ˘ 62.3 a 737.4 ˘ 58.0 b 756.6 ˘ 58.6 bc
AE 250 742.8 ˘ 46.4 a 776.7 ˘ 62.6 b 768.9 ˘ 56.1 bc
1 NC (10 mL/kg of distilled water), acarbose (10 mg/kg), phloridzin (200 mg/kg), and AE (500 mg/kg).
Treatments were co-administered orally and respectively with glucose (2 g/kg), sucrose (4 g/kg), and starch
(3 g/kg) in OGTT, OSucTT and OSTT tests. Data is expressed as means ˘ S.E.M. of six rats. Means with
different letters of the alphabet within a column are significantly different at p < 0.05, as analyzed using Tukey
HSD (honest significant difference) as a post hoc test.
Nutrients 2015, 7 7019
3.3. Oral Sucrose Tolerance Test (OSucTT) in Normal Rats
Results depicted in Figure 3 show that, in the NC group, the blood glucose levels of the sucrose-loaded
rats increased from 4.9 to 9.1 mmol/L 30 min after the oral administration of sucrose (4 g/kg), and then
it decreased to 7.3 mmol/L and 6.1 mmol/L 60 and 120 min post-loading, respectively. As observed
in OGTT, a dose of 500 mg/kg of AE significantly (p < 0.001) attenuated the elevated blood glucose
levels 30 min after sucrose loading, with the percentage of blood glucose increment being 34.3% only,
as compared with the initial glucose levels. Similar suppression pattern was observed in AE-treated
group at a dose of 250 mg/kg. With further observation, an insignificant diminution in blood glucose
levels was recorded as the levels decreased to 6.5 mmol/L and 5.5 mmol/L respectively 60 min and
120 min post-loading. On the other hand, as compared to the control group, 200 mg/kg and 10 mg/kg of
phloridzin and acarbose, respectively, significantly suppressed postprandial hyperglycemia until 60 min
after sucrose-loading. Furthermore, acarbose continued to significantly suppress glucose levels until
the end of the study. AUC readings reflected the recorded blood glucose levels, as lower AUC values
indicated lower glucose concentrations in the blood, suggesting a stronger inhibitory effect of intestinal
glucose absorption for the test substance. Hence, AUC trend was as follows: NC > AE 250 > AE 500 >
Phloridzin > Acarbose (Table 1).
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Figure 3. Effect of normal control (NC), acarbose, phloridzin and aqueous extract (AE) of
NPV on postprandial blood glucose levels in oral sucrose tolerance test. Data is expressed
as means ˘ S.E.M. (n = 6). ** p < 0.01, and *** p < 0.001 vs. the NC group.
3.4. Oral Starch Tolerance Test (OSTT) in Normal Rats
Figure 4 depicts the changes in postprandial blood glucose levels as observed in oral starch tolerance
test. Thirty min following starch administration, the blood glucose levels of NC rose up to 9.10 mmol/L.
Later, at minutes 60 and 120 after starch was administered, the glucose levels decreased to 7.46 mmol/L
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and then to 5.48 mmol/L, respectively. However, 500 mg/kg of AE significantly (p < 0.001) suppressed
postprandial hyperglycemia as obsereved 30 min after starch administration, when compared with NC,
with not more than a 37.3% rise in blood glucose levels being recorded at that point. Though statistically
insignificant, AE blood glucose lowering effect was sustained until the end of the study. Similar
observation was recorded in AE 250 group. Likewise, phlorizine, at a dose of 200 mg/kg, caused
a comparable significant suppression effect to that of acarbose (10 mg/kg) at minute 30 (p < 0.001),
as compared to NC. Both phloridzin and acarbose sustained this significant effect until minute 60
(p < 0.01 and p < 0.001, respectively). Based on AUC values in Table 1, the NC group showed the
highest concentrations of blood glucose per min, with the value being 840.6 ˘ 55.5 mmol¨min/L,
which was followed by AE 250 and AE 500 with the values of 768.9 ˘ 56.1 mmol¨min/L and
756.6 ˘ 58.6 mmol¨min/L, respectively. Yet, the AUC value of AE-treated groups was not significantly
different from that of phloridzine (685.5 ˘ 62.0 mmol¨min/L). Meanwhile, acarbose treatment showed
the lowest AUC value (623.7 ˘ 45.8 mmol¨min/L).
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3.5. In Vitro Inhibitory Effects of AE against α-Glucosidase and α-Amylase
AE inhibitory effects against α-lucosidase and α-mylase were respectively measured using
p-nitrophenyl-α-D-glucopyranoside (pNPG) and starch as substrates (Figure 5). The inhibition of
both enzyme activities was compared with that caused by a standard inhibitor, acarbose. Results
indicated that AE inhibited the activity of α-glucosidase in a dose-dependent fashion: The percentages
of activity were 0.85%, 6.36%, 15.93%, 40.28%, 69.64%, and 92.33% at the respective concentrations
of 3.13, 6.25, 12.50, 25, 50, and 100 mg/mL (Figure 5A). Likewise, the inhibitory effect of AE against
α-amylase activity occurred in a dose-dependent manner: The inhibition was intensified gradually as
AE concentrations increased from 3.13 to 100 mg/mL (Figure 5B). At the concentration of 100 mg/mL,
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AE caused the maximum inhibition for both of the enzymes. Yet, with reference to the IC50 values
of acarbose and AE, findings suggested that AE α-glucosidase and α-amylase inhibitory effects
(28.92 ˘ 0.05 and 60.62 ˘ 0.32, respectively) were weaker than those of acarbose (1.11 ˘ 0.02 and
0.45 ˘ 0.07, respectively).Figure 5 
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Figure 5. Inhibitory activities of aqueous extract (AE) of NPV on (A) α-glucosidase and
(B) α-amylase. AE inhibitory activities were determined using the respective pNPG and
starch as substrates. Acarbose was used as the positive control. Values are expressed as
means ˘ S.E.M. of triplicates. Values with different letters of the alphabet were significantly
different at p < 0.05, as analyzed using Tukey HSD (honest significant difference) as a
post hoc test. The final concentration of acarbose was 6.25 mg/mL.
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4. Discussion
Postprandial hyperglycemia is characterized by a rapid and great increase in blood glucose
levels following a meal [3]. Clinical studies have indicated that postprandial hyperglycemia is an
independent and direct risk factor for cardiovascular disease in nondiabetic and diabetic individuals [17].
Management of postprandial hyperglycemia can be achieved by influencing two physiological pathways:
(1) The digestion of complex carbohydrates into absorbable monosaccharides by carbohydrate-digestive
enzymes; and (2) intestinal absorption of those monosaccharides via intestinal glucose transporters [3].
After ingestion, polysaccharides (e.g., starch) are degraded into oligosaccharides (e.g., sucrose, maltose
and lactose) by digestive enzymes in the salivary, along with the pancreatic α-amylase. Then, those
oligosaccharides are further broken down into absorbable monosaccharides (e.g., glucose, fructose
and galactose) by the α-glucosidase located at the brush border membrane of the intestinal cells, the
enterocytes. Once glucose is available in the brush membrane border, enterocytes mediate the expression
of a Na+/glucose co-transporter, SGLT1 (sodium/glucose-linked transporter 1), and glucose is actively
transported into absorptive epithelial cells. To reach the blood circulation, it is then released from those
epithelial cells facilitated by a glucose transporter, GLUT2 (glucose transporter 2), which is located in
the basolateral membrane [18].
In a diabetic condition, insulin’s ability to stimulate cellular glucose uptake from the blood is
compromised [19]. Thus, following a meal rich in carbohydrates, controlling blood glucose at the ideal
levels becomes difficult as the body is rendered less capable of responding to released insulin, which
results in the accumulation of glucose in the blood, leading to postprandial hyperglycemia. In addition,
several studies have shown an increase in the expression of intestinal SGLT1 and the facilitative glucose
transporter gene, GLUT 2, in diabetic rats [20,21]—bodily responses which increase the rate of intestinal
glucose absorption and further contribute to the onset of postprandial hyperglycemia. The changes in the
expression of glucose transporters could be studied by several techniques, namely quantitative real-time
PCR analysis, immunohistochemistry and Western blot [22]. For instance, by isolating and quantifying
the protein and/or mRNAs of enterocytes that corresponding to SGLT1 and GLUT2 in the intestines of
control rats, diabetic rats, and treated-diabetic rats, the expression rates of those key glucose transporters
could be compared.
A study done in 2004 showed that consumption of a vinegar preparation (20 g apple cider vinegar, 40 g
water and 1 tablespoon saccharin sweetener) as a dietary supplement significantly reduced postprandial
blood glucose levels [23]. Moreover, an older study carried on using Caco-2 colon cell culture
showed vinegar to decrease the activity of a number of intestinal glucose transporters [24]. In the
present study, the effect of the aqueous extract of the vinegar of Malaysia-native Nypa fruticans on
postprandial hyperglycemia was investigated in vitro and in vivo. Both phloridzin and acarbose, standard
drugs proven to effectively attenuate postprandial glucose levels, were used as the positive controls
for comparison purpose. First, in vitro intestinal glucose absorption, investigated using isolated and
averted rat jejunum, was found to be significantly diminished in the presence of AE or phloridzin.
AE’s similitude with phloridzin indicated that it might, as well, act by exerting an inhibitory effect on
intestinal glucose transporters, as phloridzin’s principal pharmacological action has been known to be the
reduction of the intestinal glucose absorption rate via inhibition of sodium/glucose-linked transporters
(SGLTs) located in the mucosal of the small intestine [25]. On the other hand, the results indicated that
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glucose absorption was not inhibited significantly by acarbose, which was not surprising considering that
acarbose has been reported to have no significant inhibitory effect on the absorption of readily available
monosaccharides like glucose [26]. The findings of this study, hence, come in support of previous work
by Madariaga et al. [27], who reported acarbose as a selective α-glucosidase inhibitor which did not
affect monosaccaride (namely glucose) transport in vivo.
The inhibitory activity of AE was further confirmed in vivo using normal rats, which underwent oral
glucose, sucrose and starch tolerance tests. Indeed, AE at a dose of 500 mg/kg suppressed the rise in
blood glucose levels 30 min after glucose loading (2 g/kg). Phloridzin recorded a similar blood glucose
suppression effect as AE. Conversely, however, acarbose, in agreement with the in vitro findings using
rat isolated jejunum, failed to produce a significant blood glucose lowering effect in vivo after glucose
loading. In oral sucrose and starch tolerance tests, AE proved to exhibit a similar suppressive activity
on elevated blood glucose levels as that seen in OGTT. Additionally, both phloridzin and acarbose
significantly attenuated the rise in the blood glucose levels of sucrose and starch loaded rats—an effect
which was witnessed as early as in the first 30 min of the 2-h test period. The present in vivo test findings
suggest that AE probably exerted its antidiabetic effect via suppressing postprandial hyperglycemia. As
similar inhibitory effects were seen for AE and phloridzin in vitro and in vivo, with OGTT, OSucTT and
OSTT tests, it can be hypothesized that AE, in part, diminishes glucose absorption through the intestine
by inhibition of the activity of intestinal glucose transporters (the same mechanism phloridzin exhibits).
It is known that intestinal absorption of glucose is mediated by active transport carried out by the
sodium-dependent glucose transporter, SGLT1, and facilitated by the sodium-independent transporter,
GLUT2 [28]. As the findings of this study might infer, AE could be ameliorating postprandial
hyperglycemia by competing with glucose for the binding site on SGLT1, thus delaying the process
of glucose absorption from the diet. Recently, Hassimotto et al. [29] proposed that one of the intestinal
glucose uptake mechanisms influenced by an anthocyanin probably involved effects on SGLT1. To test
this hypothesis, further research is needed in order to pinpoint AE-related effects on the expression and
regulation of the facilitative glucose transporters.
On the other hand, further in vitro tests have shown AE to exhibit rather a weak inhibitory activity
against α-glucosidase and α-amylase (Figure 5), suggesting that AE plays no significant role in the
degradation of complex carbohydrates into simple monosaccharides. Intestinal α-glucosidases and
pancreatic α-amylase make up a series of carbohydrate metabolizing enzymes, which are involved in
the breakdown of complex carbohydrates into absorbable monosaccharides [30]. α-glucosidase and
α-amylase inhibitors, like acarbose, can prolong the process of carbohydrate absorption, thus forcing
glucose to enter the blood circulation in a latent, rather than a sudden, fashion, eventually attenuating
the postprandial rise in blood glucose levels [31]. Considering that AE significantly inhibited intestinal
glucose absorption in vitro, suppressed the rise of blood glucose levels in OGTT, and possessed weak
inhibitory effects on α-glucosidase and α-amylase activities, it could be safely concluded that AE
inhibited the transit and absorption of glucose and other monosaccharides in the digestive tract, rather
than interfering in the carbohydrate digestion process. Therefore, it could be speculated that the action
mechanism of AE is different from that of acarbose.
Previous HPLC analysis of AE revealed a mixture of organic acids, mainly lactic acid and acetic acid
at the percentages of 10.35% and 8.68%, respectively, followed by citric acid (6.90%), and succinic acid
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(5.85%). Malic acid was present at a fair percentage of 2.89%. Acetic acid, found to be one of the major
components of AE, has been reported extensively in several studies as having the potential of countering
postprandial hyperglycemic and promoting insulinemic responses [32]. Thus, the observed effect of AEs
on the postprandial hyperglycemia might be attributable to its acetic acid content.
5. Conclusions
Overall, the results of this study demonstrated that an aqueous extract of NPV alleviated postprandial
hyperglycemia in normolgycemic rats, at least in part, by delaying the absorption of dietary glucose
in the intestine via inhibition of intestinal glucose transporters which are located at the apical side
of the enterocytes of the small intestine. The observed suppression of postprandial hyperglycemia by
NPV further suggested promising nutraceutical use of the NPV, consumed before and during meals in
preventing hyperglycemia.
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